ライフサイエンスコーパス: median survival time

1 he Kaplan-Meier method to estimate patients' median survival time.

2 nd 10-year survival probability and estimate median survival time.

3 d 10-year survival probability and estimated median survival time.

4 nt high-dose cisplatin lavage had a 26-month median survival time.

5 hallenge, ZWC more than doubles the animals' median survival time.

6 ction was associated with a 5.5% increase in median survival time.

7 , as measured by bioluminescent imaging, and median survival time.

8 ting brain tumor with poor prognosis and low median survival time.

9 9) from 40% to 46% and a 2-month increase in median survival time (1-3).

10 nd light chain-only (LCO) patients had worse median survival times (1.9 years) than patients with IgA

11 h LIG4 rs7325927 (V) had the worst survival (median survival time, 1.2 years) and exhibited the highe

12 onged but not indefinite allograft survival (median survival time 116 days).

13 exacerbated in C57BL/6-Kit(W-sh/W-sh) mice (median survival time = 13 vs 60 days in wild-type [WT] m

14 CMV retinitis was associated with mortality (median survival time, 13.6 vs. 29.7 months; P=.007).CONC

15 ients ultimately develop gradual graft loss (median survival time = 140 d), suggesting that alloreact

16 /- CD4+ T cells acutely rejected allografts (median survival time 15 days), whereas recipients recons

17 postoperative administration of LTbetaR-Ig (median survival time: 18 vs. >50 d, respectively, P=0.00

18 nvasion and worse disease-specific survival (median survival time 20.3 versus 43.9 months, log-rank P

19 76% in patients who received other regimens (median survival time 223 days).

20 s 11% +/- 6% for vehicle-treated recipients (median survival time, 25 days) versus 63% +/- 12% for re

21 in patients diagnosed in more recent years (median survival time 3.3 years [95% CI 3.0-3.8] in 2001

22 iously reported IDEC-131-treated allografts, median survival time (35 +/- 31 days) was significantly

23 ared with patients without response (n = 61; median survival time, 35.6 months v not reached, respect

24 /- 12% for recipients treated with WHI-P131 (median survival time, 36 days; P <.0001).

25 was markedly prolonged in BALB/c recipients (median survival time, 37 and 15 days, respectively; p <

26 cal follow-up showed a significantly shorter median survival time (4.1 y, age-adjusted hazard ratios

27 cinogenesis was lowest in the control group (median survival time, 40 weeks) and highest in the group

28 itial dendritic cells, are rejected acutely (median survival time 5 days).

29 dendritic cells (DC), are rejected acutely (median survival time 5 days).

30 NA levels and CD4(+) T-cell losses and died (median survival time, 5.5 weeks).

31 for patients with a single brain metastasis (median survival time 6.5 vs 4.9 months, p=0.0393).

32 he two arms of the study with respect to the median survival time (6.3 months for the gemcitabine plu

33 with better-than-expected survival (14-month median survival time; 61% 1-year, 32% 2-year, and 30% pr

34 pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving

35 eceiving hemodynamic support alone survived (median survival times 65 vs 85 hours, respectively; P =

36 .9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate,

37 97440 (V) and HMGA2 rs1563834 (V) genotypes (median survival time, 7.8 years).

38 Ten-year OS estimates (43% v 34%) and median survival times (8.7 v 7.3 years) favored ADT and

39 blockade in addition to lethal irradiation (median survival time, 81 days) when compared to mice tha

40 was 65% overall, 48% in the BDex+AA cohort (median survival time 821 days), and 76% in patients who

41 ion (4.1 v 4.6 months), or overall survival (median survival time, 9.3 months v 10.2 months; P = .74)

42 erved with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate,

43 Median survival time after diagnosis of t-MDS/t-AML was

44 The median survival time after HCC diagnosis for persons wit

45 Median survival time after study enrollment was greater

46 Median survival time after TAVI was 3.4 years (95% confi

47 The median survival time among men who experienced progressi

48 streactivation growth kinetics and prolonged median survival times among infected animals.

49 ast 8.2% of the subjects in this cohort, and median survival times among men with LOY were 5.5 years

50 Median survival times among patients with CR/PR, SD, or

51 With a minimum follow-up of 24 months, the median survival time and 1- and 2-year survival rates we

52 The overall response rate was 60%, with a median survival time and 1-year survival probability of

53 Response rate was the primary end point; median survival time and 1-year survival rate were secon

54 Median survival time and 1-year survival rates were 6.6

55 ediction was assessed by using difference in median survival time and area under the curve with time-

56 The median survival time and OS rate at 12 months for this r

57 ligonucleotides (Group 3) did not affect the median survival time and the 35-day survival rate as com

58 Median survival time and time to progression were 11.4 a

59 Median survival times and 2-year survival rates for pati

60 Median survival times and 2-year survival rates for pati

61 h R0, R1 (<1 mm), and R1 (direct) status the median survival times and 5-year survival rates were 41.

62 etween percent maximal cytoreduction and log median survival time, and this correlation remained sign

63 However, the median survival times are similar to those with single-a

64 r differentiation according to difference in median survival time between high- and low-risk groups (

65 The differences in median survival times between persons in the lower and u

66 The differences in median survival times between persons in the lower and u

67 atients with multiple myeloma, extending the median survival time by on average 20%.

68 The median survival times by GPA score and diagnosis were de

69 Predicted median survival time calculated according to the Helsink

70 The median survival time, censored to liver transplantation,

71 The median survival time estimate was 389 days (95% CI, 267

72 The median survival time for 33 patients was 33.7 months.

73 The median survival time for all 402 eligible patients was 9

74 Median survival time for all patients was 15 months, wit

75 an time to progression was 21 weeks, and the median survival time for all patients was 19.9 months.

76 Median survival time for all patients with +8 was 9.9 mo

77 In 81 patients, the median survival time for EGFR/FISH-negative patients was

78 For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.

79 Median survival time for low-risk, intermediate-risk, an

80 The median survival time for overweight (2.64 y; range: 0.23

81 The median survival time for patients with low social attach

82 The median survival time for patients with TS <or= 7.5 x 10(

83 In an exact-matched case analysis (n = 38), median survival time for RSR13 patients was 7.3 months v

84 The median survival time for the 27 AML patients randomly as

85 The median survival time for women with optimally debulked a

86 The median survival times for all patients, those with gliob

87 The median survival times for favorable-, intermediate-, and

88 treated controls (P < 0.0001); corresponding median survival times for groups b, c, and d were 36 (P

89 Median survival times for patients in quartiles one, two

90 Median survival times for the standard and experimental

91 spholipase A(2) IVa) (Group 4) increased the median survival time from 6 to 35 days and the 35-day su

92 progressing neurodegenerative disease with a median survival time from diagnosis of 1.5-3 years.

93 The median survival time from the time of diagnosis is appro

94 Median survival times from onset were 43 years (white fe

95 survived at the study endpoint, leading to a median survival time greater than 83 days (at least 32%

96 se mice as compared to control counterparts (median survival time, >70 vs 9.5 days).

97 For participants in cohort 1, the median survival time had not been reached at 174 days, w

98 At a median follow-up of 30.2 months, the median survival time has not been reached and the 2-year

99 After the amendment to add bevacizumab, the median survival time has not yet been reached for FOLFIR

100 unistic illness (OI) diagnosed in 1984-1997, median survival time improved from 11 months for 1984 di

101 ART to 57% in the HAART era (P = .0006), and median survival time improved from 8.3 to 43.2 months (P

102 Among patients with stage-specific data, the median survival time improved from 84 months (95% CI, 81

103 levant tissues and a significant increase in median survival time in a dose-dependent manner.

104 Median survival time in months varied by tumor type: met

105 amelteon or melatonin significantly improved median survival time in rats (sepsis/melatonin [0.1 mg/k

106 The median survival time in the FOLFOX plus SIRT group was 2

107 Median survival time in the intermediate-risk group was

108 Median survival time in the pemetrexed/cisplatin arm was

109 The median survival time in the phase II portion was 14 mont

110 Therapy usually fails and the median survival time is < 6 months.

111 urvival after systemic therapy; the reported median survival time is 7 to 17 months.

112 The median survival time is 9-12 months, with neither chemot

113 Observed median survival times, Kaplan-Meier survival curves, pro

114 e prognosis for these patients is poor, with median survival times measured in months.

115 The median survival time (MST) and 1-year survival rate was

116 arrow cells displayed a significantly longer median survival time (MST) compared with mice that recei

117 Median survival time (MST) for cisplatin/pemetrexed was

118 ct against host-type breast cancer cells, as median survival time (MST) increased from 25.6 +/- 2.6 (

119 R mice accepted K skin grafts with increased median survival time (MST) more than 169 days compared t

120 C3H donor corneal allograft survival, with a median survival time (MST) of 21 days.

121 esis of IFN-gamma and NOS2 mRNA, and with an median survival time (MST) of 258.5 d.

122 oside (E), and radiation (XRT) resulted in a median survival time (MST) of 26 months.

123 For thymectomized rats, the median survival time (MST) of limb allograft in non-trea

124 tment with MPA-loaded nanogels increased the median survival time (MST) of lupus-prone NZB/W F1 mice

125 Chemotherapy alone yields a median survival time (MST) of no more than 10 months and

126 Median survival time (MST) was 14.9 months; by stage, MS

127 Median survival time (MST) was 20.6 months (95% CI, 14.0

128 =2); when given at 25 mg/kg twice daily, the median survival time (MST) was 27 days (n=4).

129 The median survival time (MST) was 5.4 months for the efapro

130 with recipients infused with wild-type SPC (median survival time (MST): 38 vs. 92 days, P=0.02).

131 marrow cells (1.0x10(5) cells per recipient, median survival time (MST)=41 days vs. 2.5x10(7) cells p

132 metB mutant were highly virulent, with mouse median survival times (MST) of 28.5 and 42 days, respect

133 al was assessed by clinical examination, and median survival times (MST) were calculated.

134 Donor-specific islet grafts were accepted (median survival time [MST] > 180 days, n=6), whereas all

135 on of CIITA greatly enhanced graft survival (median survival time [MST] 36 days) over the survival of

136 compared with treatment with vehicle alone (median survival time [MST] AR-C117977 treated 15; 19 and

137 nificantly delayed by CD8+ T-cell depletion (median survival time [MST], 35 days) when compared to un

138 tched animals that rejected skin in 11 days (median survival time [MST], n=6) and hearts in 35 days (

139 val to 19 days compared with untreated mice (median survival time [MST]=10 days).

140 ) in eyes of normal BALB/c and C57BL/6 mice (median survival times, MST, 16 and 10 days, respectively

141 llograft survival in C3H/HeJ mice, extending median survival times (MSTs) beyond 100 days.

142 therapeutic advances, which have doubled the median survival time, myeloma continues to be a mostly i

143 ases (LBDs; majority Parkinson disease [PD]; median survival time not reached).

144 with stable or progressive disease (n = 56; median survival time, not reached v 36 months, respectiv

145 e clinician better outcomes than the current median survival time of 1 year for patients with sclerod

146 hose with an SUVr of at least 2.5, who had a median survival time of 10.1 (95% CI: 2.4, 15.9; P = .00

147 <or= 4.9 x 10(-3) (40 of 50 patients) had a median survival time of 10.2 months, compared with 1.9 m

148 deaths from lung cancer were documented with median survival time of 10.3 months (interquartile range

149 interval, 71% of patients were alive, with a median survival time of 10.9 months.

150 glioblastoma with a penetrance of 92% and a median survival time of 105 d.

151 H-SRT was well tolerated and resulted in a median survival time of 11 months after H-SRT, independe

152 nths), 71.6% of patients were deceased, with median survival time of 11 months for those who died.

153 The median survival time of 12.5 months for patients who rec

154 aster than single-mutant littermates, with a median survival time of 136 days (versus 158 days in p53

155 the central nervous system associated with a median survival time of 15 months, even with aggressive

156 rimary end point was successfully met with a median survival time of 15.3 months.

157 ths, 55 patients (76%) have died, yielding a median survival time of 18.3 months (95% CI, 14.6 to 22.

158 ion of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FO

159 sepsis without any treatment (Group 1) had a median survival time of 2 days and a zero (0) percent su

160 9 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, l

161 r final cohort included 118 patients, with a median survival time of 21 months from the time of recur

162 5% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts wit

163 tients with SUVr of less than 1.7, who had a median survival time of 23.1 months (95% confidence inte

164 rvival was noted in CCR2-/- recipients, with median survival time of 24 and 12 days for CCR2-/- and W

165 Survival analysis demonstrated a median survival time of 24 months (95% confidence interv

166 0), and 5-8 (n=17) unfavorable genotypes had median survival time of 24.2, 16.4, 14.4, 9.6, and 7.4 m

167 Patients with 0 to 1 abnormality had a median survival time of 25 months (n = 26; 95% CI, 13-46

168 al pneumonia, is a fatal lung disease with a median survival time of 3-5 years.

169 neuromuscular degenerative disorders, with a median survival time of 3-5 years.

170 eceived a salvage autotransplantation; their median survival time of 30 months was only slightly bett

171 5% maximal cytoreduction had a mean weighted median survival time of 33.9 months--an increase of 50%.

172 med severe multi-organ GVHD and died after a median survival time of 37 days.

173 complete and six partial responses), with a median survival time of 44 weeks (9.5 months).

174 peritoneal (IP) chemotherapy have reported a median survival time of 49 to 63 months and 2-year survi

175 In contrast, the poor-risk group had a median survival time of 5 months.

176 (35%) died over the follow-up period, with a median survival time of 5.6 years.

177 is with antibiotic treatment (Group 2) had a median survival time of 6 days and a 35-day survival rat

178 oma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously r

179 Although D2 skin grafts were rejected with a median survival time of 63.8 days in B10.A mice given AL

180 In addition, the median survival time of 9 months was less than the survi

181 n follow-up time of 53 months, the actuarial median survival time of all eligible patients was 38.5 m

182 Median survival time of all registered patients was 9 mo

183 astoma is a universally lethal cancer with a median survival time of approximately 15 months.

184 These loci resulted in a reduction of median survival time of at least eight and five months i

185 fibrinogen-coated oil droplets improved the median survival time of B16F10 melanoma-bearing mice fro

186 10-30 mg/kg/day significantly increased the median survival time of BN heart allografts from 7 to 18

187 t 20-30 mg/kg/day significantly extended the median survival time of BN kidney allograft recipients f

188 The median survival time of breast cancer patients with brai

189 d those who receive standard regimens have a median survival time of less than 1 year.

190 ection followed by radiotherapy (RT), with a median survival time of less than 10 months.

191 e growth of T24 xenografts and increases the median survival time of nude mice.

192 The median survival time of patients with GBM is under 10 mo

193 carcinomas revealed a striking reduction in median survival time of patients with high beta6 express

194 prevalence of idiopathic pulmonary fibrosis, median survival time of patients, and potential risk fac

195 Median survival time of rats bearing orthotopic glioma w

196 ll registered patients was 9 months, and the median survival time of resected patients was 13 months.

197 and breast cancer xenografts and doubled the median survival time of TCL1-Tg:p53(-/-) mice, which dev

198 mg/kg intraperitoneally, tid) prolonged the median survival time of the BMT recipients to 56 days.

199 The median survival time of the entire cohort was 9.2 months

200 ions, were used to assess the effects on log median survival time of the proportion of each cohort un

201 The median survival time of the SPCTNFRIIFc mice was 142 day

202 e liver and adrenal glands and increased the median survival time of the tumor-bearing mice.

203 ; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, resp

204 rolonged allograft survival (P=0.0007), with median survival times of 14.5 days for Neoral alone, 7 d

205 CNSL face a particularly poor prognosis with median survival times of 2-12 months despite aggressive

206 e, two, or three or more at-risk alleles had median survival times of 27.5, 14.4, and 9.9 months, res

207 with those without diabetes (P < .001), with median survival times of 3 months for long-term diabetic

208 five, and six to seven adverse genotypes had median survival times of 36.2, 23.9, 16.3, 13.0, and 8.3

209 Median survival times of 393 v 98 days for a positive ve

210 Median survival times of 6 months for the ITT and 8.3 mo

211 s, with the highly significant difference in median survival times of 68 and >216 months, respectivel

212 with those without diabetes (P = .02), with median survival times of 9 months for long-term diabetic

213 The median survival times of all patients, patients with LM,

214 and also have a poor prognosis with reported median survival times of less than 6 months.

215 elderly patients have remained dismal, with median survival times of only a few months.

216 ound an overall survival trend favoring TEM; median survival times of patients treated with DTIC and

217 was corresponding to a 7.8-month decrease in median survival time (P = 9.5 x 10(-14)).

218 estimated the time ratio (relative change in median survival time) per 100 working level months (rado

219 it remains uniformly incurable with a dismal median survival time post-treatment of 3-4 years.

220 treating early-stage micrometastases, giving median survival times similar to those obtained with ant

221 than 25% MCM2 immunoreactivity had a longer median survival time than patients with > or = 25% MCM2

222 Animals that received FUS+DOX (N=8) had a median survival time that was increased significantly (P

223 Treatment with (a) increased median survival time to 34 days compared with 29 days fo

224 d antibody-conjugated liposome (b) increased median survival time to 38 days (P = 0.0002 relative to

225 tment with 120 muCi (213)Bi-7.16.4 increased median survival time to 41 days compared with 28 days fo

226 limus but not by CsA at the equivalent dose (median survival time: untreated, 6 days; tacrolimus, 18

227 classical predisposing host factors, and the median survival time was <4 months after diagnosis.

228 The median survival time was 10.8 months for the patient pop

229 The median survival time was 10.9 months (95% CI, 7.8 to 14.

230 low-up of 28.5 months (for living patients), median survival time was 11.8 months (95% CI, 7.4 to 19.

231 In these 194 patients, the median survival time was 12.5 months (95% CI, 9.1 to 15.

232 The median survival time was 1257 days.

233 The overall median survival time was 131 d (95% confidence interval,

234 Median survival time was 14 months among patients with p

235 The median survival time was 14 months, and the 1- and 2-yea

236 median follow-up of 14 months, the predicted median survival time was 14 months, and the 1-year survi

237 The median survival time was 14 months.

238 after a diagnosis of esophageal cancer, the median survival time was 14.9 months (IQR, 7.1-52.3 mo)

239 Median survival time was 145 days as opposed to 78 days,

240 Median survival time was 15 months for the FISH-positive

241 a median follow-up time of 38.7 months, the median survival time was 15.8 months.

242 low-, intermediate-, and high-dose arms, the median survival time was 16, 14, and 13 months, respecti

243 The median survival time was 16.3 (11.47-22.57) months, and

244 The median survival time was 16.3 (11.47-22.57) months, and

245 The median survival time was 19.2, 14.7, and 13.2 months for

246 edian time to progression was 4.9 weeks, and median survival time was 19.7 weeks.

247 Median survival time was 20.0 months (95% CI, 5.0 to 43.

248 Median time to progression was 3 months, and median survival time was 20.2 months.

249 The median survival time was 21 months (95% confidence inter

250 od of 23 months (range, 9 to 40 months), the median survival time was 22.3 months (95% confidence int

251 , with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 11

252 The median survival time was 24.7 months.

253 The median survival time was 257 days, but differed consider

254 Median survival time was 26 months.

255 signed to receive Sr-89 and doxorubicin, the median survival time was 27.7 months (4.9-37.7), and for

256 ival (EFS) time once in CR was 36 weeks, and median survival time was 28 weeks.

257 The median survival time was 28.7 months for patients in arm

258 years [SD 7.2], 54% female, 91% white), the median survival time was 3.8 years (95% CI 3.5-3.8).

259 Median survival time was 33.0 weeks for oral and 35.0 we

260 The median survival time was 35 months, and the most common

261 hs (range, 7.7 to >or= 42.0 months), and the median survival time was 35.8 months (range, 8.8 to >or=

262 Median survival time was 36 and 22 months for groups A a

263 The median survival time was 36 mo (range, 12-216 mo) from d

264 At a median follow-up time of 10 months, median survival time was 42 weeks (95% CI, 19.1 to 86.6

265 Median time to progression was 305 days, and median survival time was 451 days.

266 r, the 2-year survival rate was 91%, and the median survival time was 51 months.

267 Median survival time was 53.6 months for women with decr

268 Median survival time was 6.31 months for patients treate

269 The median survival time was 6.7 months for exatecan plus ge

270 Median survival time was 6.9 months.

271 The median survival time was 7 months, and the 1-year surviv

272 In the intent-to-treat population, median survival time was 7.7 months for patients treated

273 ee survival was 2.9 months for each arm, and median survival time was 8.3 versus 7.9 months (P = not

274 Median survival time was 8.4 months (95% CI, 4.8 to 13.9

275 The median survival time was 8.6 months in the combination-t

276 s 2.3 months (95% CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95% CI, 6.2 to 12.6

277 CEGT did not extend survival; the median survival time was 81.9 months (95% CI, 64.8 to 99

278 The median survival time was 82 days (interquartile range [I

279 Of 17 patients with known EGFR status, median survival time was 9.3 months for those with wild-

280 Results were considered promising if the median survival time was at least 21 months and of no fu

281 Median survival time was decreased in anti-CD54-treated

282 Graft median survival time was extended from 5 to 10 days and

283 ficacy was greater in the MM model, in which median survival time was increased more than 4.5-fold.

284 The median survival time was less than 6 months in the poor-

285 ship between platinum dose-intensity and log median survival time was not statistically significant.

286 Median survival time was poorest in non-GBM patients wit

287 Median survival time was significantly prolonged in the

288 The response rate and median survival time were 20% and 8.2 months, respective

289 Median survival times were 111, 105, 125, and 167 days,

290 The median survival times were 17.6 months (95% CI, 16.1 to

291 Median survival times were 232 and 302 days, respectivel

292 The median time to progression and median survival times were 30 and 49 weeks for arm 1, 21

293 Median survival times were 6.3 months for IRINOGEM (95%

294 Median survival times were 6.5 and 9.7 months, respectiv

295 Median survival times were 6.7 months (95% CI, 5.8 to 7.

296 nths vs 8.4 months, respectively, P = .046), median survival times were not statistically different (

297 rated using L1210JF or KG-1 cells, increased median survival times were obtained with f-L-DOX treatme

298 to be detrimental because historical overall median survival times were similar to those of nonrespon

299 Retrospective analysis suggested prolonged median survival time with pertuzumab compared with histo

300 Median survival time without IRA failure was estimated a